₹3,282 Cr
₹-627 Cr
--
As on 22-Sep-2023 IST
₹-4.40
•
-1.90%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Wockhardt
| 1.95 | -1.60 | -0.52 | -10.45 | -5.32 | -15.62 | -8.31 |
|
S&P BSE Healthcare
| 20.54 | -0.92 | 10.55 | 20.23 | 12.28 | 12.24 | 11.52 |
|
S&P BSE Small Cap
| 28.11 | 4.28 | 13.75 | 26.74 | 35.95 | 18.64 | 21.05 |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Wockhardt
| -41.22 | -24.12 | 132.57 | -55.75 | -43.41 | 41.60 | -58.99 |
|
S&P BSE Small Cap
| -1.80 | 62.77 | 32.11 | -6.85 | -23.41 | 59.64 | 1.77 |
|
S&P BSE Healthcare
| -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 | -12.88 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Wockhardt Ltd. stood at ₹ 7,683 Cr as on 30-Jun-23
The share price of Wockhardt Ltd. is ₹227.400000 (NSE) and ₹227.750000 (BSE) as of 22-Sep-2023 IST. Wockhardt Ltd. has given a return of -5.32% in the last 3 years.
Wockhardt Ltd. has a market capitalisation of ₹ 3,282 Cr as on 22-Sep-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Wockhardt Ltd. is 1.02 times as on 22-Sep-2023, a -0.69% premium to its peers’ median range of 3.28 times.
Since, TTM earnings of Wockhardt Ltd. is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Wockhardt Ltd. and enter the required number of quantities and click on buy to purchase the shares of Wockhardt Ltd..
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. It also provides contract manufacturing services. The company was founded in 1967 and is headquartered in Mumbai, India.
The prominent promoters of Wockhardt Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Themisto Trustee Company Private Limited |
47.36%
|
|
Pasithee Trustee Company Private Limited |
3.07%
|
|
Ananke Trustee Company Private Limited |
2.89%
|
|
Callirhoe Trustee Company Private Limited |
2.89%
|
The chairman of the company is Habil Khorakiwala, and the managing director is Murtaza Khorakiwala.
The promoters of Wockhardt Ltd. have pledged 40.34% of the total equity as on Jun-23.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,148
|
|
|
8,069
|
|
|
7,910
|
|
|
7,585
|
| Wockhardt Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-19.92
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0.07
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Wockhardt Ltd. was ₹-627 Cr.
₹3,281.75 Cr
₹2,700.00 Cr
₹-627.00 Cr
₹124.00 Cr
₹1,887.00 Cr
58.40%
High
₹145.15 - 269.10
₹5.00
14,40,94,573
BSE: 532300, NSE: WOCKPHARMA
Aurangabad, Maharashtra
www.wockhardt.com
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It... develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. It also provides contract manufacturing services. The company was founded in 1967 and is headquartered in Mumbai, India. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
Add Portfolio 